These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. Stoltze Gaborit F; Bosselmann H; Kistorp C; Iversen K; Kumler T; Gustafsson F; Goetze JP; Sölétormos G; Tønder N; Schou M BMC Cardiovasc Disord; 2016 May; 16():117. PubMed ID: 27246703 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of CD34+ Stem Cell Therapy in Nonischemic Dilated Cardiomyopathy Is Absent in Patients With Diabetes but Preserved in Patients With Insulin Resistance. Vrtovec B; Sever M; Jensterle M; Poglajen G; Janez A; Kravos N; Zemljic G; Cukjati M; Cernelc P; Haddad F; Wu JC; Jorde UP Stem Cells Transl Med; 2016 May; 5(5):632-8. PubMed ID: 27025690 [TBL] [Abstract][Full Text] [Related]
6. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. Truong QA; Januzzi JL; Szymonifka J; Thai WE; Wai B; Lavender Z; Sharma U; Sandoval RM; Grunau ZS; Basnet S; Babatunde A; Ajijola OA; Min JK; Singh JP Heart Rhythm; 2014 Dec; 11(12):2167-75. PubMed ID: 25014756 [TBL] [Abstract][Full Text] [Related]
7. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Lok DJ; Lok SI; Bruggink-André de la Porte PW; Badings E; Lipsic E; van Wijngaarden J; de Boer RA; van Veldhuisen DJ; van der Meer P Clin Res Cardiol; 2013 Feb; 102(2):103-10. PubMed ID: 22886030 [TBL] [Abstract][Full Text] [Related]
8. Effects of Repetitive Transendocardial CD34 Vrtovec B; Poglajen G; Sever M; Zemljic G; Frljak S; Cerar A; Cukjati M; Jaklic M; Cernelc P; Haddad F; Wu JC Circ Res; 2018 Jul; 123(3):389-396. PubMed ID: 29880546 [TBL] [Abstract][Full Text] [Related]
9. Effects of Transendocardial CD34 Bervar M; Kozelj M; Poglajen G; Sever M; Zemljic G; Frljak S; Cukjati M; Cernelc P; Haddad F; Vrtovec B Stem Cells Transl Med; 2017 Jun; 6(6):1515-1521. PubMed ID: 28296283 [TBL] [Abstract][Full Text] [Related]
10. Galectin-3 predicts left ventricular remodelling after anterior-wall myocardial infarction treated by primary percutaneous coronary intervention. Di Tano G; Caretta G; De Maria R; Parolini M; Bassi L; Testa S; Pirelli S Heart; 2017 Jan; 103(1):71-77. PubMed ID: 27465055 [TBL] [Abstract][Full Text] [Related]
11. Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy. Poglajen G; Sever M; Cukjati M; Cernelc P; Knezevic I; Zemljic G; Haddad F; Wu JC; Vrtovec B Circ Cardiovasc Interv; 2014 Aug; 7(4):552-9. PubMed ID: 25097199 [TBL] [Abstract][Full Text] [Related]
12. GALECTIN-3 AS A PROGNOSTIC BIOMARKER IN PATIENTS WITH NON-HODGKIN LYMPHOMA. Samura B Georgian Med News; 2015 Nov; (248):7-11. PubMed ID: 26656543 [TBL] [Abstract][Full Text] [Related]
13. Plasma and Cardiac Galectin-3 in Patients With Heart Failure Reflects Both Inflammation and Fibrosis: Implications for Its Use as a Biomarker. Besler C; Lang D; Urban D; Rommel KP; von Roeder M; Fengler K; Blazek S; Kandolf R; Klingel K; Thiele H; Linke A; Schuler G; Adams V; Lurz P Circ Heart Fail; 2017 Mar; 10(3):. PubMed ID: 28288987 [TBL] [Abstract][Full Text] [Related]
14. Immunologic Network and Response to Intramyocardial CD34+ Stem Cell Therapy in Patients With Dilated Cardiomyopathy. Haddad F; Sever M; Poglajen G; Lezaic L; Yang P; Maecker H; Davis M; Kuznetsova T; Wu JC; Vrtovec B J Card Fail; 2015 Jul; 21(7):572-82. PubMed ID: 25863169 [TBL] [Abstract][Full Text] [Related]
15. Galectin-3 in Patients with Acute Heart Failure: Preliminary Report on First Polish Experience. Sygitowicz G; Tomaniak M; Filipiak KJ; Kołtowski Ł; Sitkiewicz D Adv Clin Exp Med; 2016; 25(4):617-23. PubMed ID: 27629834 [TBL] [Abstract][Full Text] [Related]
16. Galectin-3 predicts response and outcomes after cardiac resynchronization therapy. Andre C; Piver E; Perault R; Bisson A; Pucheux J; Vermes E; Pierre B; Fauchier L; Babuty D; Clementy N J Transl Med; 2018 Nov; 16(1):299. PubMed ID: 30390680 [TBL] [Abstract][Full Text] [Related]
17. Prospective Validation of a Screening Biomarker Approach Combining Amino-Terminal Pro-Brain Natriuretic Peptide With Galectin-3 Predicts Death and Cardiovascular Events in Asymptomatic Hemodialysis Patients. Voroneanu L; Siriopol D; Apetrii M; Hogas S; Onofriescu M; Nistor I; Kanbay M; Dumea R; Cusai S; Cianga P; Constantinescu D; Covic A Angiology; 2018 May; 69(5):449-455. PubMed ID: 28974104 [TBL] [Abstract][Full Text] [Related]
19. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Motiwala SR; Szymonifka J; Belcher A; Weiner RB; Baggish AL; Sluss P; Gaggin HK; Bhardwaj A; Januzzi JL Eur J Heart Fail; 2013 Oct; 15(10):1157-63. PubMed ID: 23666680 [TBL] [Abstract][Full Text] [Related]
20. Association of Galectin-3 and Soluble ST2, and Their Changes, with Echocardiographic Parameters and Development of Heart Failure after ST-Segment Elevation Myocardial Infarction. Tymińska A; Kapłon-Cieślicka A; Ozierański K; Budnik M; Wancerz A; Sypień P; Peller M; Balsam P; Opolski G; Filipiak KJ Dis Markers; 2019; 2019():9529053. PubMed ID: 31687050 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]